Emerging biologics in the treatment of uveitis

Expert Review of Clinical Immunology

Volumn 3, Issue 5, 2007, Pages 781-796

  Yeh, Steven ^a   Nussenblatt, Robert B ^a   Levy Clarke, Grace A ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ATLIZUMAB; AZATHIOPRINE; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CHEMOKINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ANAPHYLAXIS; ANEMIA; ANTIBODY PRODUCTION; APLASTIC ANEMIA; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL INFECTION; BIOLOGICAL THERAPY; BLOOD TOXICITY; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DEMYELINATION; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EYE INFLAMMATION; FEVER; FLU LIKE SYNDROME; HEADACHE; HERPES ZOSTER; HUMAN; HYPOTENSION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; KIDNEY CARCINOMA; LUNG EMBOLISM; LUPUS LIKE SYNDROME; LYMPHOCYTE COUNT; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDIATOR; MELANOMA; MONOTHERAPY; MYALGIA; MYCOSIS; NAUSEA; NEURALGIA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; OPTIC NEURITIS; PAIN; PANCYTOPENIA; PATHOGENESIS; PSORIASIS; REVIEW; RIGOR; SEPSIS; SIDE EFFECT; SKIN CANCER; SKIN DEFECT; SKIN DISEASE; THROMBOCYTOPENIA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VIRAL GASTROENTERITIS; VIRUS INFECTION; VIRUS REACTIVATION; VITREOUS HEMORRHAGE; VOMITING;

EID: 34748875401     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.5.781     Document Type: Review

References (134)

1. Nussenblatt RB. Elements of the immune system and concepts of intraocular inflammatory disease pathogenesis. In: Uveitis: Fundamental and Clinical Practice. Nussenblatt RB, Whitcup SM (Eds). Mosby, PA, USA 3-46 (2004).
2. Albini T, Rao N. Immunologic processes in ocular disease. In: Pathobiology of Ocular Disease: a Dynamic Approach (3rd Edition). Klintworth GK (Ed.) M. Dekker, NY, USA (2007) (In press).
3. Sugita S, Futagami Y, Smith SB, Naggar H, Mochizuki M. Retinal and ciliary body pigment epithelium suppress activation of
4. T lymphocytes via transforming growth factor β. Exp. Eye Res. 83(6), 1459-1471 (2006).
5. Farrokh-Siar L, Rezai KA, Semnani RT, Patel SC, Ernest JT, van Seventer GA. Human fetal retinal pigment epithelium suppresses the activation of CD4(+) and CD8(+) T-cells. Graefes Arch. Clin. Exp. Ophthalmol. 237(11), 934-939 (1999).
6. Osusky R, Dorio RJ, Arora YK, Ryan SJ, Walker SM. MHC class II positive retinal pigment epithelial (RPE) cells can function as antigen-presenting cells for microbial superantigen. Ocul. Immunol. Inflamm. 5(1), 43-50 (1997).
7. Chan CC, Wetzig RP, Palestine AG, Kuwabara T, Nussenblatt RB. Immunohistopathology of ocular sarcoidosis. Report of a case and discussion of immunopathogenesis. Arch. Ophthalmol. 105(10), 1398-1402 (1987).
8. George RK, Chan CC, Whitcup SM, Nussenblatt RB. Ocular immunopathology of Behcet's disease. Surv. Ophthalmol. 42(2), 157-162 (1997).
9. Takase H, Sugita S, Taguchi C, Imai Y, Mochizuki M. Capacity of ocular infiltrating T helper type 1 cells of patients with non-infectious uveitis to produce chemokines. Br. J. Ophthalmol. 90(6), 765-768 (2006).
10. Foxman EF, Zhang M, Hurst SD et al. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Thl- versus Th2-mediated ocular inflammation. J. Immunol. 168(5), 2483-2492 (2002).
11. Perez VL, Papaliodis GN, Chu D, Anzaar F, Christen W, Foster CS. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul. Immunol. Inflamm. 12(3), 193-201 (2004).
12. de Boer JH, van Haren MA, de Vries-Knoppert WA et al. Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr. Eye Res. 11, 181-186 (1992).
13. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
14. van Kooij B, RothovaA, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am. J. Ophthalmol. 142(1), 192-194 (2006).
15. Caspi RR, Roberge FG, Chan CC et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140(5), 1490-1495 (1988).
16. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature 286(5773), 611-613 (1980).
17. Kim MK, Chan CC, Nussenblatt RB, Palestine AG. Pharmacologic effects on the expression of class II histocompatibility antigen in experimental endotoxin-induced uveitis. Clin. Immunol. Immunopathol. 45(1), 70-77 (1987).
18. Yamaki K, Takiyama N, Itho N et al. Experimentally induced Vogt-Koyanagi-Harada disease in two Akita dogs. Exp. Eye Res. 80(2), 273-280 (2005).
19. Malik AB. Endothelial cell interactions and integrins. New Horiz. 1(1), 37-51 (1993).
20. Xu H, Forrester JV, Liversidge J, Crane IJ. Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest. Ophthalmol. Vis. Sci. 44(1), 226-234 (2003).
21. Uchio E, Kijima M, Tanaka S, Ohno S. Suppression of experimental uveitis with monoclonal antibodies to ICAM-1 and LFA-1. Invest. Ophthalmol. Vis. Sci. 35(5), 2626-2631 (1994).
22. Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB, Chan CC. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin. Immunol. Immunopathol. 67(2), 143-150 (1993).
23. Whitcup SM, Hikita N, Shirao M et al. Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis. Exp. Eye Res. 60(6), 597-601 (1995).
24. Whitcup SM, Chan CC, Li Q, Nussenblatt RB. Expression of cell adhesion molecules in posterior uveitis. Arch. Ophthalmol. 110(5), 662-666 (1992).
25. Martin CM, Santos Lacomba M, Serrano Molina CI, Ramirez Chamond R, Collantes Estevez E. ICAM-1 expression on the surface of T lymphocytes in patients with uveitis: a comparative study between the eye and peripheral blood. Ophthalmologica 216(3), 203-208 (2002).
26. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am. J. Ophthalmol. 140(3), 509-516 (2005).
27. Jabs DA, Rosenbaum JT, Foster CS et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol. 130(4), 492-513 (2000).
28. Jabs DA, Akpek EK. Immunosuppression for posterior uveitis. Retina 25(1), 1-18 (2005).
29. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108(6), 1134-1139 (2001).
30. Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul. Immunol. Inflamm. 11(2), 131-139 (2003).
31. Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112(8), 1472-1477 (2005).
32. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin. Experiment Ophthalmol. 31(6), 487-491 (2003).
33. Akpek EK, Baltatzis S, Yang J, Foster CS. Long-term immunosuppressive treatment of serpiginous choroiditis. Ocul. Immunol. Inflamm. 9(3), 153-167 (2001).
34. Vianna RN, Ozdal PC, Deschenes J, Burnier MN Jr. Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Can. J. Ophthalmol. 41(2), 183-189 (2006).
35. Nussenblatt RB, de Smet MD, Rubin B et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am. J. Ophthalmol. 115(5), 583-591 (1993).
36. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology 105(11), 2028-2034 (1998).
37. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114(5), 1000-1006 (2007).
38. Murphy CC, Greiner K, Plskova J et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch. Ophthalmol. 123(5), 634-641 (2005).
39. Akpek EK, Jabs DA, Tessler HH, Joondeph BC, Foster CS. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 109(8), 1506-1513 (2002).
40. Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 109(1), 137-142 (2002).
41. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33(4), 231-237 (2006).
42. Lipsky PE, van der Heijde DM, St Clair EW et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343(22), 1594-1602 (2000).
43. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor ct monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354(9194), 1932-1939 (1999).
44. Hanauer SB, Feagan BG, Lichtenstein GR et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 359(9317), 1541-1549 (2002).
45. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled rnulticentre trial. Lancet 359(9313), 1187-1193 (2002).
46. Suhler EB, Smith JR, Wertheim MS et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch. Ophthalmol. 123(7), 903-912 (2005).
47. Abu EI-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease. Int. Ophthalmol. 26(3), 83-92 (2005).
48. Lanthier N, Parc C, Scavennec R, Dhote R, Brezin AP, Guillevi L. Infliximab in the treatment of posterior uveitis in Behcet's disease. Long term follow up in four patients. Presse Med. 34(13), 916-918 (2005).
49. Tugal-Tutkun I, Mudun A, Urgancioglu M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cydosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 52(8), 2478-2484 (2005).
50. Wechsler B, Sable-Fourtassou R, Bodaghi B et al. Infliximab in refractory uveitis due to Behcet's disease. Clin. Exp. Rheumatol. 22(4 Suppl. 34), S14-S16 (2004).
51. Sayarlioglu M, Cinal A, Topcu N, Demirok A. Effect of infliximab on refractory uveitis in Behcet's disease. Ann. Pharmacother. 38(5), 901-902 (2004).
52. Giansanti F, Barbera ML, Virgili G, Pieri B, Emmi L, Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur. J. Ophthalmol. 14(5), 445-448 (2004).
53. Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: efficacy in joint and ocular disease. Ann. Rheum. Dis. 66(6), 840-841 (2007).
54. Richasds JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin. Exp. Ophthalmol. 33(5), 461-468 (2005).
55. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113(2), 308-314 (2006).
56. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113(5), 864.el-864.e2 (2006).
57. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-α therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109(12), 2342-2346 (2002).
58. Fries W, Giofre MR, Catanoso M, Lo Gullo R. Treatment of acute uveitis assodated with Crohn's disease and sacroileitis with infliximab. Am. J. Gastroenterol. 97(2), 499-500 (2002).
59. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor a blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111 (2), 352-356 (2004).
60. Cazabon S, Over K, Butcher J. The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye 19(2), 222-224 (2005).
61. El-Shabrawi Y, Hermann J. Anti-TNF α therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye 19(9), 1017-1018 (2005).
62. Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J. Clin. Rheumatol. 12(6), 291-293 (2006).
63. Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea 24(6), 742-744 (2005).
64. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med. Wkly 132(29-30), 414-422 (2002).
65. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am. J. Gastroenterol. 97(12), 2962-2972 (2002).
66. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology (Oxf.) 42(5), 617-621 (2003).
67. Lanthier N, Parc C, Scavennec R, Dhote R, Brezin AP, Guillevi L. Infliximab in the treatment of posterior uveitis in Behce's disease. Long term follow up in four patients. Presse Med. 34(13), 916-918 (2005).
68. Mejico LJ. Infliximab-associated retrobulbar optic neuritis. Arch. Ophthalmol. 122(5), 793-794 (2004).
69. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44(2), 265-267 (2007).
70. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 56(5), 1433-1439 (2007).
71. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A; Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm. Rep. 54(RR-15), 49-55 (2005).
72. Wang JY. Diagnosis of tuberculosis by an enzyme-linked immunospot assay for interferon-γ Emerg. Infect. Dis. 13(4), 553-558 (2007).
73. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J. Pediatr. 149(4), 572-575 (2006).
74. Biester S, Deuter C, Michels H et al. Adalimumab in the therapy of uveitis in childhood. 91(3), 319-324 (2007).
75. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease. 21(6), 824-825 (2007).
76. van Laas JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab; a new modality for Behcet's disease? Ann. Rheum. Dis. 66(4), 565-566 (2007).
77. van der Heijde D, Kivitz A, Schiff MH et al; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(7), 2136-2146 (2006).
78. Schiff MH, Burmester GR, Kent JD et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 65(7), 889-894 (2006).
79. Avunduk MC, Avunduk AM, Oztekin E, Baltaci AK, Ozyazgan Y, Mogolkoc R. Etanercept treatment in the endotoxin-induced uveitis of rats. Exp. Eye Res. 79(3), 357-365 (2004).
80. Koizumi K, Poulaki V, Doehmen S et al. Contribution of TNF-α to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest. Ophthalmol. Vis. Sci. 44(5), 2184-2191 (2003).
81. Klareskog L, van der Heijde D, de Jager JP et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (9410), 675-681 (2004).
82. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340(4), 253-259 (1999).
83. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342(11), 763-769 (2000).
84. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50(7), 2264-2272 (2004).
85. Calin A, Dijkmans BA, Emery P et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis. 63(12), 1594-1600 (2004).
86. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxf.) 44(8), 1008-1011 (2005).
87. Smith JA, Thompson DJ, Whitcup SM et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 53(1), 18-23 (2005).
88. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113(12), 2317-2323 (2006).
89. Smith BJ, McMillan VM, Newton JS. Corticosteroid-sparing effect of etanercept in idiopathic panuveitis resistant to immunosuppressive therapy. J. Clin. Rheumatol. 7(3), 175-178 (2001).
90. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br. J. Ophthalmol. 87(7), 925 (2003).
91. Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul. Immunol. Inflamm. 14(3), 145-150 (2006).
92. Tauber T, Turetz J, Barash J, Avni I, Morad Y. Optic neuritis associated with etanercept therapy for juvenile arthritis. J. AAPOS 10(1), 26-29 (2006).
93. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFα agents. J. Pediatr. 149(6), 833-836 (2006).
94. Caspi RR, McAllister CG, Gery I, Nussenblatt RB. Differential effects of cyclosporins A and G on functional activation of a T-helper-lymphocyte line mediating experimental autoimmune uveoretinitis. Cell Immunol. 113(2), 350-360 (1988).
95. Totun N, Callizo J, Orlic N, Scherer M, Hartmann C, Pleyer U. Serum cytokine receptor levels in noninfectious uveitis. Ophthalmic Res. 37(2), 112-116 (2005).
96. Martin CM, Lacomba MS, Molina CI, Chamond RR, Galera JM, Estevez EC. Levels of soluble ICAM-1 and soluble IL-2R in the serum and aqueous humor of uveitis patients. Curr. Eye Res. 20(4), 287-292 (2000).
97. Nussenblatt RB, Fortin E, Schiffman R et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a Phase I/II clinical trial. Proc. Natl Acad. Sci. USA. 96(13), 7462-7466 (1999).
98. Nussenblatt RB, Thompson DJ, Li Z et al. Humanized anti-interleukin-2 (IL-2) receptor α therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun. 21(3), 283-293 (2003).
99. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110(4), 786-789 (2003).
100. Flynn JM, Byrd JC. Campath-lH monoclonal antibody therapy. Curr. Opin. Oncol. 12(6), 574-581 (2000).
101. Cheung WW, Hwang GY, Tse E, Kwong YL. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab, Haematologica 91 (5 Suppl.), ECR13 (2006).
102. Willis F, Marsh JC, Bevan DH et al. The effect of treatment with Campath-lH in patients with autoimmune cytopenias. Br. J. Haematol. 114(4), 891-898 (2001).
103. Dick AD, Meyer P, James T et al. Campath-1H therapy in refractory ocular inflammatory disease. Br. J. Ophthalmol. 84(1), 107-109 (2000).
104. Isaacs JD, Hale G, Waldmann H et al. Monoclonal antibody therapy of chronic intraocular inflammation using Campath-lH. Br. J. Ophthalmol. 79(11), 1054-1055 (1995).
105. Klastersky J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr. Opin. Oncol. 18(4), 316-320 (2006).
106. Lira W-K, Fujimoto C, Ursea R et al. Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch. Ophthalmol. 123(7), 957-963 (2005).
107. Thomas PB, Albini T, Giri RK, See RF, Evans M, Rao NA. The effects of atorvastatin in experimental autoimmune uveitis. Br. J. Ophthalmol. 89(3), 275-279 (2005).
108. Luna JD, Chan CC, Derevjanik NL et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor α, and interleukin-1β-mediated breakdown. J. Neurosci. Res. 49(3), 268-280 (1997).
109. de Vos AF, Klaren VN, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest. Ophthalmol. Vis. Sci. 35(11), 3873-3883 (1994).
110. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(3), 614-624 (2002).
111. Reiff A. The use of anakinra in juvenile arthritis. Curr. Rheumatol. Rep. 7(6), 434-440 (2005).
112. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201(9), 1479-1486 (2005).
113. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52(6), 1794-1803 (2005).
114. Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br. J. Ophthalmol. 91 (2), 263-264 (2007).
115. Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxf.) 46(6), 1042-1043 (2007).
116. Benezra D, Maftzir G, Barak V. Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behcet disease. Am. J. Ophthalmol. 123(5), 593-598 (1997).
117. Whitcup SM, DeBarge LR, Rosen H, Nussenblatt RB, Chan CC. Monoclonal antibody against CD11b/CD18 inhibits endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 34(3), 673-681 (1993).
118. Takiguchi R, Tofte S, Simpson B et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J. Am. Acad. Dermatol. 56(2), 222-227 (2007).
119. Dubertret L, SterryW, Bos JD et al; CLEAR Multinational Study Group. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a Phase III internadonal randomized, placebo-controlled trial. Br. J. Dermatol. 155(1), 170-181 (2006).
120. Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch. Dermatol. 141(1), 31-38 (2005).
121. Leonardi CL, Toth D, Cather JC et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 213(3), 204-214 (2006).
122. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol. 29(2 Suppl. 6), 18-22 (2002).
123. Cohen SB, Emery P, Greenwald MW et al; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a muldcenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793-2806 (2006).
124. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56(4), 1263-1272 (2007).
125. Kiln H, Csaky KG, Chan CC et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp. Eye Res. 82(5), 760-766 (2006).
126. Maini RN, Taylor PC, Szechinski J et al; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54(9), 2817-2829 (2006).
127. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50(6), 1761-1769 (2004).
128. Woo P, Wilkinson N, Prieur AM et al. Open label Phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 7(6), R1281-R1288 (2005).
129. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders. Hematology Am. Soc. Hematol. Educ. Program. 1, 283-296 (2004).
130. Ogawa J, Harigai M, Akashi T et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann. Rheum. Dis. 65(12), 1667-1669 (2006).
131. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865-876 (2006).
132. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005).
133. Thiel MA, Steiger JU, O'Connell PJ, Lehnert AM, Coster DJ, Williams KA. Local or short-term systemic costimulatory molecule blockade prolongs rat corneal allograft survival. Clin. Experiment Ophthalmol. 33(2), 176-180 (2005).
134. Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. J. Rheumatol. 33(11), 2124-2131 (2006).